Anticancer agent 317
Anticancer agent 317, a Chidamide (HY-109015) derivative, is an apoptosis inducer. Anticancer agent 317 inhibits colony formation, migration, adhesion, invasion, tumor growth, and angiogenesis. Anticancer agent 317 can be used for the research of breast cancer.
For research use only. We do not sell to patients.
- CAS No.: 3117779-13-9
- Formula: C47H47ClFN9O3S
- Molecular Weight:872.45
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Anticancer agent 317 (Compound 6e) potently and selectively inhibits proliferation of MDA-MB-231 breast cancer cells with an IC50 of 0.10 μM[1].
Anticancer agent 317 (0.025-0.1 μM; 24 h) dose-dependently inhibits long-term colony formation of MDA-MB-231 breast cancer cells, with significant inhibition observed at concentrations as low as 0.025 μM[1].
Anticancer agent 317 (0.025-0.1 μM; 48 h) dose-dependently induces apoptosis in MDA-MB-231 breast cancer cells, with the highest level of apoptosis observed at 0.1 μM[1].
Anticancer agent 317 (0.01-0.04 μM; 24 h) dose-dependently inhibits adhesion of MDA-MB-231 breast cancer cells, with significant inhibition observed at concentrations as low as 0.01 μM[1].
Anticancer agent 317 (0.01-0.04 μM; 24-48 h) dose-dependently inhibits invasion of MDA-MB-231 breast cancer cells, with significant inhibition observed at concentrations as low as 0.01 μM[1].
Anticancer agent 317 (0.025-0.1 μM) dose-dependently inhibits angiogenesis and tumor growth in a chicken embryo CAM model of breast cancer, with the 0.1 μM dose reducing tumor weight to 8.33 mg and angiogenesis to 51.79% of control levels[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MDA-MB-231
-
Concentration:0.025 μM; 0.05 μM; 0.1 μM
-
Incubation Time:24 h
-
Result:Dose-dependently reduced colony-forming ability of MDA-MB-231 cells, with colony formation rates of 66.17% at 0.025 μM, 50.00% at 0.05 μM, and 33.46% at 0.1 μM.
Showed stronger inhibitory activity than chidamide (86.07% colony formation rate) at 0.1 μM.
-
Cell Line:MDA-MB-231
-
Concentration:0.025 μM; 0.05 μM; 0.1 μM
-
Incubation Time:48 h
-
Result:Dose-dependently increased the proportion of Annexin V-positive apoptotic cells.
Markedly elevated the proportion of apoptotic cells (Annexin V-positive, PI-positive/negative) compared to untreated control at 0.1 μM, with 21.16% of cells in the early apoptotic quadrant and 29.33% in the late apoptotic quadrant.
-
Cell Line:MDA-MB-231
-
Concentration:0.01 μM; 0.02 μM; 0.04 μM
-
Incubation Time:24 h; 48 h
-
Result:Inhibited migration capacity at both 24 h and 48 h.
Reduced migration rates to 66.65% at 0.01 μM, 50.42% at 0.02 μM, and 30.99% at 0.04 μM after 48 h.
Showed stronger inhibitory activity than chidamide (51.69% migration rate at 48 h) at 0.04 μM.
Chemical Information
-
CAS No. 3117779-13-9
-
Molecular Weight 872.45
-
Formula C47H47ClFN9O3S
-
SMILES
CC1=NN=C2[C@@H](N=C(C3=C(N12)SC(C)=C3C)C4=CC=C(C=C4)Cl)CC(NCCCCCCNC5=CC(F)=CC=C5NC(C6=CC=C(C=C6)CNC(/C=C/C7=CC=CN=C7)=O)=O)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Anticancer agent 317 Related Classifications
HY-183302 Related Classifications
Powered by Bioz